There is no sense in suspending the work of enterprises and certain sectors of the Russian economy due to the spread of COVID-19. This was announced on October 13 by the head of Rospotrebnadzor Anna Popova during the online conference “Pandemic 2020: challenges, solutions, consequences.”
“This experience of the system as a whole for the population of the entire country <...> allows us to feel quite confident <...>, despite the fact that we see growth figures, today in the Russian Federation we are not talking about blocking the economy and stopping any -that <...> enterprises, ”TASS quotes her.
The head of Rospotrebnadzor stressed that the risks will be minimal if all the requirements for the prevention of coronavirus are met, if people are not adherents of “covid nihilism” and, in particular, wear masks and gloves in public places.
Popova also noted that the level of coverage of the population with PCR testing for coronavirus is not decreasing. According to her, the subjects of the country do at least 155 tests per 100 thousand people a day in each settlement.
She called the key task of Rospotrebnadzor and other departments to prevent “COVID dissidence” in relation to vaccination against coronavirus infection and the importance of an information campaign in this direction.
“The vaccine is something that will certainly give us much more confidence in the epidemiological situation, its forecasting and blocking its further development,” she stressed.
The world’s first coronavirus vaccine was registered on August 11 in Russia. The drug, developed by the specialists of the Gamaleya Center, was named “Sputnik V”.
The second vaccine against coronavirus infection was developed by the Vector Research Center. On September 30, the center received patents for a drug called EpiVacCorona. Pre-registration studies will begin in November-December.
October 11 at the Center for Research and Development of Immunobiological Preparations named after M.P. Chumakov spoke about the progress of clinical trials of their vaccine against COVID-19.